# Day-One-rNPV-rDCF-v2
updated rNPV and DCF models evaluating OJEMDA and DAWN ev
rNPV: $1.038b valuation of Ojemda (tovorafenib) MOA (BRAF, BRAF v600)
DCF: $480m valuation of Day One Biopharma
